Q5146 Injection, hercessi, 10 milligrams
Also known as: trastuzumab biosimilar, Hercessi, HER2-positive therapy
Injection of trastuzumab-hercessi (Hercessi), a biosimilar to trastuzumab, administered at 10 milligrams per dose.
In Plain Language
breast cancer medication; HER2 blocker injection; monoclonal antibody
Clinical Context
Used for HER2-positive breast cancer and gastric cancer. Administered intravenously as part of multimodal oncologic therapy. Binds to human epidermal growth factor receptor 2.
RVU Information
CPT Q5146 does not have a physician work RVU assigned by CMS. Reimbursement for this code is determined by payer-specific fee schedules.
Billing & Documentation
Q-codes are temporary HCPCS codes used when no permanent code exists. Coverage and reimbursement vary by payer and region. Document the clinical indication and medical necessity. These codes may be replaced by permanent codes in future HCPCS updates.
Specialties
Frequently Asked Questions
What is CPT code Q5146?
CPT Q5146 (Injection, hercessi, 10 milligrams) is a Q Codes code. Injection of trastuzumab-hercessi (Hercessi), a biosimilar to trastuzumab, administered at 10 milligrams per dose.
Is Q5146 covered by insurance?
Q5146 is a temporary HCPCS code. Coverage varies by payer and may change when permanent codes are assigned. Used for HER2-positive breast cancer and gastric cancer. Administered intravenously as part of multimodal oncologic therapy. Binds to human epidermal growth factor receptor 2.
When is CPT Q5146 used?
Used for HER2-positive breast cancer and gastric cancer. Administered intravenously as part of multimodal oncologic therapy. Binds to human epidermal growth factor receptor 2.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against national data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.